Gilead’s growing HIV franchise; cell therapy licensing deals plummet
This week's PharmaVoice newsletter highlights Gilead's latest FDA-approved HIV combination pill, a sharp decline in cell therapy licensing deals, the FDA's planned public hearing on psychedelics, and Eli Lilly's $2.8 billion acquisition of AtaiBeckley.
Gilead’s growing HIV franchise; cell therapy licensing deals plummet
This week's PharmaVoice newsletter highlights Gilead's latest FDA-approved HIV combination pill, a sharp decline in cell therapy licensing deals, the FDA's planned public hearing on psychedelics, and Eli Lilly's $2.8 billion acquisition of AtaiBeckley.
As measles outbreaks soar, where does drug R&D stand?
The measles outbreak in the United States has reached a 30-year high, but the therapeutic drug development pipeline remains sparse. A few companies like Invivyd are advancing antibody candidates, while GSK has pushed a quadrivalent vaccine into Phase III trials. Politicization and declining public trust have intensified prevention and control difficulties, while the compliance costs and time of the MMR vaccine split executive order may deter companies.
Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts
This week, Novartis and Bristol-Myers Squibb paused several CAR-T therapy trials for autoimmune diseases due to serious safety incidents, with Novartis reporting three deaths. The news caused fluctuations in related companies' stock prices, analysts began assessing the impact, and multiple developers emphasized differences in their therapy process designs to reduce expectations of risk transmission.
China’s clinical trial boom under scrutiny after 3 deaths come to light
China's clinical trials are known for their speed and cost advantages, but three deaths reported over the summer, including two children, have raised questions about U.S. FDA data review and regulatory transparency.
PatientSight announces the launch of the Patient Experience Benchmark Report. | PharmaVoice
PatientSight announced the launch of the Patient Experience Benchmark Report (PEBR), which is based on primary research with patients affected by rare and complex diseases, converting qualitative journey insights into comparable quantitative metrics to support performance evaluation and improvement across patient populations and therapeutic areas. The report is available in both customized and syndicated formats, accompanied by executive presentations or an interactive platform with AI query capabilities.
Medical Communications Teams Spend Months Building Scientific Narratives. MEDSTORY•AI® Delivers a Defensible First Draft in 90 Minutes. | PharmaVoice
Medical communication teams have long struggled with multiple review rounds and high costs. SBC's MEDSTORY•AI, through its proprietary story angle library and core story concepts, delivers three complete citation-output drafts in 90 minutes, drastically shortening the traditional 1-to-4-month delivery cycle.
Cresset releases Flare V12 to cut synthesis and testing cycles with faster, more flexible FEP | PharmaVoice
Cresset releases Flare V12, aimed at accelerating compound screening and decision-making in drug discovery through faster, more flexible FEP technology that lowers computational costs and supports complex chemical transformations.
Kairos Meridian Launches An Independent, Shorter Path From Problem to Impact | PharmaVoice
Kairos Meridian was officially established on June 30, 2026, in Millstone Township, New Jersey, USA, as an independent life sciences commercial consulting firm specializing in marketing, data, analytics, omnichannel, and innovation. It aims to help pharmaceutical and life sciences commercial teams find clear direction and achieve measurable impact in an environment where data, channels, and AI tools are increasingly abundant but focus is blurred.